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Cancer	cells	exploit	 the	expression	of	 the	programmed	death-1	(PD-1)	 ligand	1	(PD-L1)	 to	 subvert	 T-cell	 mediated	 immunosurveillance1,2.	 	 The	 success	 of	therapies	 that	 disrupt	 PD-L1	 mediated	 tumour	 tolerance	 has	 highlighted	 the	need	 to	 understand	 the	 molecular	 regulation	 of	 PD-L1	 expression1.	 Using	 a	genome-wide	 CRISPR/Cas9	 screen	 we	 identified	 the	 uncharacterized	 protein	CMTM6	 to	 be	 a	 critical	 regulator	 of	 PD-L1	 in	 a	 broad	 range	 of	 cancer	 cells.	CMTM6	is	a	ubiquitously	expressed,	protein	that	binds	PD-L1	and	maintains	its	cell	 surface	 expression.	 CMTM6	 is	 not	 required	 for	 PD-L1	 maturation	 but	 co-localizes	with	PD-L1	at	the	plasma	membrane	and	in	recycling	endosomes	where	it	prevents	PD-L1	from	being	targeted	for	lysosome-mediated	degradation.	Using	a	 quantitative	 approach	 to	 profile	 the	 entire	 plasma	 membrane	 proteome	 we	find	that	CMTM6	displays	remarkable	specificity	for	PD-L1.	Importantly,	CMTM6	depletion	 decreases	 PD-L1	 without	 compromising	 cell	 surface	 expression	 of	MHC	 Class	 I.	 	 CMTM6	 depletion,	 via	 the	 reduction	 of	 PD-L1,	 significantly	alleviates	 the	 suppression	of	 tumour	 specific	T-cell	 activity	 in	vitro	 and	 in	vivo.	These	 findings	 provide	 novel	 insights	 into	 the	 biology	 of	 PD-L1	 regulation,	identify	 a	 previously	 unrecognised	 master	 regulator	 of	 this	 critical	 immune	checkpoint	 and	 highlight	 a	 new	 potential	 therapeutic	 target	 to	 overcome	immune	evasion	by	tumour	cells.			 	
Manuscript	The	 interaction	 between	 PD-1	 on	 T-cells	 and	 PD-L1	 on	 tumour	 cells,	 inhibits	activation,	expansion	and	effector	functions	of	antigen	specific	CD8+	T	cells	and	helps	 cancer	 cells	 evade	 immune	 destruction1,2.	 PD-L1	 expression	 may	 be	induced	 in	 response	 to	 inflammatory	 cytokines	 such	 as	 interferon-	 γ	 (IFN-γ)	secreted	by	immune	cells	within	the	tumour	microenvironment	or	can	be	driven	by	tumour	cell	intrinsic	mechanisms,	including	amplification	of	the	PD-L1	locus3	and	structural	variation	of	the	3’	region	of	the	PD-L1	gene4.			To	 identify	new	regulators	of	both	 constitutive	 and	 induced	cell	 surface	PD-L1	expression,	we	performed	a	whole	genome	CRISPR/Cas9	deletion	library	screen5	in	the	pancreatic	cancer	cell	line	BxPC-3,	which	displays	endogenous	PD-L1	that	can	 be	 further	 induced	 with	 IFN-γ	 (Figure	 1a	 and	 Extended	 Data	 Fig.	 1).	Following	 stimulation	with	 IFN-γ,	 our	 screen	 identified	 the	key	 components	 of	the	 IFN-γ	 pathway	 as	 well	 as	 CKLF-like	 MARVEL	 trans-membrane	 domain-containing	protein	6	(CMTM6)	(Figure	1b).	In	the	absence	of	IFN-γ,	CMTM6	was	the	 only	 identified	 regulator	 of	 PD-L1	 expression	 (Figure	 1c).	 Depletion	 of	CMTM6	using	specific	sgRNAs	or	short	hairpin	RNAs	(shRNAs)	led	to	a	dramatic	reduction	 in	 total	 cellular	 levels	 of	 PD-L1	 (Figure	 1d	 and	 Extended	 Data	 Fig.	1c/d).	 	These	 findings	have	broad	 relevance	as	CMTM6	 is	 a	major	 regulator	of	PD-L1	 expression	 in	 cell	 lines	 representative	 of	 melanoma,	 breast	 and	 lung	cancer	(Figure	1e	and	Extended	Data	Fig.	2&3),	diseases	that	respond	to	immune	checkpoint	blockade1,2.	Importantly,	CMTM6	depletion	reduces	both	constitutive	and	 IFN-γ	 induced	 PD-L1	 expression	 without	 compromising	 antigen	presentation	by	reducing	cell	surface	MHC	class	I	 levels	(Extended	Data	Fig.	4).	Exogenous	expression	of	CMTM6	in	CMTM6	knockout	cells	regulates	PD-L1	in	a	dose	 dependent	manner	 and	 restores	 both	 total	 and	 cell	 surface	 PD-L1	 levels	(Figure	1f	and	Extended	Data	Fig.	5a).	In	myeloid	lineage	cells,	CMTM6	depletion	specifically	 downregulates	 cell	 surface	 expression	 of	 PD-L1	 but	 not	 PD-L2	(Extended	 Data	 Fig.	 6a/b).	 Interestingly,	 CMTM6	 levels	 are	 not	 influenced	 by	IFN-γ	 stimulation	 (Extended	Data	 Fig.	 1c,	 4b	 and	5b)	 and,	 in	 contrast	 to	 other	recently	described	regulators	of	PD-L1	expression1,2,	CMTM6	does	not	 function	
as	a	transcriptional	regulator	of	PD-L1	either	in	the	presence	or	absence	of	IFN-γ	(Figure	1g).			CMTM6	belongs	to	a	family	of	proteins,	primarily	encoded	by	two	distinct	gene	clusters,	on	chromosome	16	(CMTM1-4)	and	chromosome	3	(CMTM6-8)6.	Whilst	largely	 uncharacterised,	 CMTM	 family	 members	 contain	 a	 MARVEL	 domain	comprising	 at	 least	 three	 transmembrane	 helices7.	 Interestingly,	 MARVEL	domain	 proteins	 have	 been	 implicated	 in	 regulating	 trafficking	 of	transmembrane	 and	 secretory	 proteins7.	 To	 determine	 whether	 CMTM6	interacts	 with	 PD-L1,	 we	 performed	 reciprocal	 co-immunoprecipitation	experiments	 using	 detergent	 conditions	 that	 solubilise	 the	 membrane	 to	 a	variable	 degree.	 CMTM6	 was	 readily	 detected	 in	 association	 with	 PD-L1;	however,	this	interaction	is	maintained	only	under	conditions	that	preserve	the	integrity	 of	 a	membrane-associated	 complex	 (Figure	 2a/b).	 In	 agreement	with	this,	CMTM6	co-localises	with	PD-L1	at	the	cell	surface	both	in	the	presence	and	absence	of	IFN-γ	stimulation	(Figure	2c	and	Extended	Data	Fig.	5c/d).			As	 CMTM6	 is	 an	 uncharacterised	 protein	 localised	 at	 the	 cell	 surface,	 we	investigated	what	 other	 proteins	 associate	with	 CMTM6	under	 conditions	 that	preserve	 its	 membrane-dependent	 interactions.	 CMTM6	 was	immunoprecipitated	 from	digitonin	 lysates	of	 IFN-γ	 treated	cells	and	subjected	to	mass	 spectrometry	 analysis.	 After	 eliminating	 proteins	 identified	 in	 control	immunoprecipitates,	only	a	small	number	of	high	confidence	interacting	proteins	were	 identified,	of	which	PD-L1	was	one	of	 the	top	ranked	(Extended	Data	Fig.	6c).		To	gain	a	comprehensive	unbiased	overview	of	plasma	membrane	proteins	whose	 expression	 is	 altered	 following	 CMTM6	depletion,	we	 combined	plasma	membrane	 enrichment	 through	 selective	 aminoxy-biotinylation	 (Plasma	Membrane	 Profiling;	 PMP)8	 with	 Tandem	 Mass	 Tag	 (TMT)-based	 quantitative	proteomics9	(Figure	2d).	Following	CRISPR/Cas9	mediated	disruption	of	CMTM6	with	two	independent	sgRNAs	(Figure	1d),	we	exploited	10-plex	TMT	labelling	to	profile	 the	 cell	 surface	 proteome	 of	 wild-type	 and	 CMTM6-depleted	MDA-MB-231	 breast	 cancer	 cells	 in	 triplicate.	 In	 total,	 4935	 proteins	 were	 quantitated,	including	1424	proteins	previously	reported	to	localise	to	the	plasma	membrane.	
Notably,	 PD-L1	was	 one	 of	 only	 4	 proteins	 reproducibly	 decreased	more	 than	two-fold	 from	 the	plasma	membrane	 (Figure	2e).	Taken	 together,	 the	 absolute	requirement	 for	 CMTM6	 for	 PD-L1	 cell	 surface	 expression	 and	 the	 physical	association	between	CMTM6	and	PD-L1,	 establish	CMTM6	as	a	new	regulatory	target	 to	 specifically	 vary	 the	 cell	 surface	 expression	 of	 this	 critical	 immune	checkpoint	molecule.		PD-L1	is	a	type	I	transmembrane	protein	with	four	N-linked	glycans,	which	when	modified	 by	 Golgi-resident	 enzymes	 become	 resistant	 to	 EndoH	 digestion	permitting	visualisation	of	PD-L1	trafficking	through	the	secretory	pathway.	To	examine	the	maturation	of	newly	synthesised	PD-L1,	IFN-γ	stimulated	cells	were	pulse-labelled	 with	 [35S]-cysteine-methionine.	 EndoH-resistant	 PD-L1	 species	emerged	at	a	similar	rate	 in	control	and	CMTM6	knockout	cells,	 indicating	that	loss	of	CMTM6	does	not	impair	PD-L1	export	from	the	ER	and	trafficking	beyond	the	medial	Golgi		(Figure	3a).		Whilst	PD-L1	levels	in	the	early	part	of	the	chase	were	 equivalent	 in	 wild-type	 and	 CMTM6	 knockout	 cells,	 accelerated	degradation	 of	 EndoH-resistant	 PD-L1	 was	 evident	 at	 later	 time-points	(Extended	 data	 Fig	 6d).	 Consistent	 with	 this,	 PD-L1	 cell	 surface	 expression	increases	 in	 CMTM6	 knockout	 cells	 for	 the	 first	 6	 hours	 after	 adding	 IFN-γ	(Extended	 Data	 Fig.	 6e-g),	 but	 beyond	 this	 time	 point	 only	wild-type	 cells	 are	able	to	further	augment	and	sustain	PD-L1	expression	(Extended	Data	Fig.	6e/f).	Together,	these	findings	show	that	CMTM6	is	not	required	for	the	trafficking	of	PD-L1	 from	 the	 endoplasmic	 reticulum	 (ER)	 to	 the	 cell	 surface,	 but	 may	 be	required	for	stable	expression	of	PD-L1	at	the	plasma	membrane.		To	 establish	 whether	 CMTM6	 regulates	 PD-L1	 at	 the	 cell	 surface,	 we	 labelled	surface	PD-L1	with	PD-L1-specific	antibodies	at	40C	before	transferring	cells	 to	370C	to	allow	PD-L1	internalisation	and	either	degradation	or	recycling	back	to	the	plasma	membrane	(Figure	3b-e).	 	When	evaluated	either	by	flow	cytometry	(Figure	 3b/c)	 or	 immunoprecipitation	 (Figure	 3d/e),	 degradation	 of	 antibody-labelled	PD-L1	from	the	cell	surface	was	markedly	accelerated	in	the	absence	of	CMTM6,	 whilst	 cell	 surface	 MHC	 class	 I	 labelled	 under	 the	 same	 conditions	remained	 stable	 (Extended	 Data	 Fig.	 7a).	 To	 understand	 how	 CMTM6	 may	
function	to	stabilise	cell	surface	PD-L1,	we	examined	the	subcellular	localisation	of	 CMTM6	 using	 confocal	 immunofluorescence	 microscopy	 (Figure	 3f).	 In	addition	 to	 its	 expression	 at	 the	 plasma	membrane,	 CMTM6	 is	 predominantly	identified	 in	 recycling	 endosomes	where	 it	 co-localises	with	 TFRC	 and	RAB11,	molecules	 that	 define	 the	 endocytic	 recycling	 compartment10	 (Figure	 3f).	Subcellular	 localisation	 of	 PD-L1	 also	 identified	 PD-L1	 in	 recycling	 endosomes	(Figure	3f	and	Extended	Data	Fig.	7b).		Strikingly,	incubation	with	primaquine,	an	inhibitor	of	endocytic	recycling11,	induced	rapid	loss	of	PD-L1	from	the	surface	of	wild-type	 cells	 suggesting	 that	 a	 large	 proportion	 of	 surface	 PD-L1	 is	continuously	internalised	and	recycled	(Figure	3g	and	Extended	data	Fig.	8a).		In	contrast,	 primaquine	 did	 not	 substantially	 increase	 the	 PD-L1	 internalisation	rate	in	CMTM6	knockout	cells	implying	that	the	failure	to	maintain	PD-L1	at	the	plasma	 membrane	 in	 the	 absence	 of	 CMTM6	 is	 primarily	 due	 to	 defective	endocytic	 recycling	 (Figure	 3g).	 In	 support	 of	 this,	we	 found	using	 established	recycling	 assays12,	 that	 in	 control	 cells	 the	 majority	 of	 internalised	 PD-L1	recycled	back	to	the	cell	surface	after	10	to	15	min;	however,	 in	the	absence	of	CMTM6	PD-L1	recycling	was	markedly	 impaired	(Figure	3h	and	Extended	Data	Fig.	 8b/c).	 These	 data	 demonstrate	 that	 endocytosed	 PD-L1	 is	 not	 effectively	recycled	in	CMTM6	deficient	cells	and	may	instead	be	rerouted	for	degradation	in	 the	 lysosome.	 Consistent	 with	 this,	 incubation	 with	 inhibitors	 of	 lysosomal	acidification	 stabilises	 PD-L1	 in	 CMTM6	 deficient	 cells	 (Figure	 4a-d	 and	Extended	Data	Fig	9a/b/c);	however,	PD-L1	remains	sequestered	within	the	cell	and	cannot	recycle	to	the	cell	surface	(Figure	4e	and	Extended	Data	Fig	9d).			The	 success	 of	 anti-cancer	 therapies	 targeting	 the	 PD-1/PD-L1	 immune	checkpoint	 lies	 in	 their	 ability	 to	 potentiate	 anti-tumour	 immunity13.	 	 Clinical	data	 supporting	 the	 value	 of	 anti-PD-1/PDL1	 blockade	 is	 most	 advanced	 in	melanoma14	so	we	used	co-culture	experiments	with	melanoma	cells	to	evaluate	the	 effects	 of	 CMTM6	 depletion	 on	 T-cell	 responses.	 Co-culture	with	 Jurkat	 T-cells,	which	respond	to	PD-1	inhibition15	showed	that	tumours	depleted	of	either	CMTM6	or	PD-L1	potentiated	Jurkat	IL-2	secretion	to	a	similar	degree	(Extended	data	 Fig	 9e).	 To	 extend	 these	 findings	 using	 primary	 cells,	 we	 isolated	 and	expanded	 antigen-specific	 cytotoxic	 T-lymphocyte	 clones	 (CTL)	 recognizing	
distinct	HLA-restricted	 epitopes	 from	 the	 cancer	 testis-antigen	NY-ESO-1	 from	melanoma	patients16,17.	These	CTLs	were	co-cultured	with	the	HLA-A2	NY-ESO-1	positive	 melanoma	 line	 A375	 and	 early	 passage	 HLA-Cw3	 positive	 NY-ESO-1	positive	 cell	 lines	 derived	 from	 primary	 melanoma	 patient	 samples16.	 These	melanoma	lines	were	 incubated	with	 IFN-γ	prior	 to	co-culture	to	 induce	PD-L1	expression	[Extended	data	Fig.	9f-h].	Melanoma	cells	with	decreased	cell	surface	expression	of	PD-L1	following	CMTM6	knockout	were	killed	more	efficiently	by	NY-ESO-1157-165	and	NY-ESO-192-100	specific	CTLs,	which	expressed	high	levels	of	PD-1	 (Extended	 Data	 Fig.	 10a-e).	 	Moreover,	 co-culture	with	 CMTM6	 depleted	tumour	cells	significantly	enhanced	T-lymphocyte	activation	as	 indicated	by	an	increased	proportion	of	 perforin	 and	TNF-α	producing	CD8+	T-cells	 (Figure	4f	and	Extended	Data	Fig.	10f),	 increased	IFN-γ	and	Il-2	secretion	(Figure	4g)	and	augmented	 production	 of	 pro-inflammatory	 chemokines	 (Extended	 Data	 Fig.	10g).	 	 Notably,	 deleting	 PD-L1	 or	 adding	 a	 saturating	 concentration	 of	 PD-1	blocking	antibody	to	the	co-culture	enhanced	T-cell	activation	to	a	similar	degree	as	CMTM6	depletion	(Figure	4f/g).			To	 examine	 the	 effects	 of	 CMTM6	 on	 tumour	 control	 in	 vivo	 we	 used	 RNAi	 to	deplete	 CMTM6	 in	 B16F10	 murine	 melanoma	 expressing	 the	 foreign	 antigen	chicken	 ovalbumin	 (OVA)	 to	 enhance	 the	 immunogenicity	 of	 the	 tumours.	Survival	 of	 mice	 transplanted	 with	 CMTM6-depleted	 cells	 was	 significantly	increased	 compared	 to	 control	 shRNA-expressing	 cells	 (Figure	 4h).	 This	reflected	overall	attenuated	growth	of	CMTM6-deficient	 tumours,	despite	some	inter-	and	intra-experimental	variability	in	the	responses,	which	may	represent	the	contribution	of	PD-L1	expressed	 in	 the	tumour	microenvironment.	 	 (Figure	4i	 and	 Extended	 data	 Fig	 10h-j).	 Together	 our	 ex	vivo	 human	 data	 and	 in	 vivo	mouse	 data	 demonstrate	 that	 CMTM6	 functions	 as	 a	 key	 regulator	 of	 T-lymphocyte	 mediated	 anti-tumour	 immunity	 by	 modulating	 cell	 surface	expression	of	PD-L1.		Harnessing	 the	 immune	 system	 has	 emerged	 as	 one	 of	 the	 essential	 pillars	 of	therapy	in	oncology.		Key	to	this	success	has	been	the	development	of	drugs	that	release	the	constraints	of	 immune	checkpoints1	and	insights	 into	the	molecular	
regulation	 of	 essential	 checkpoint	 molecules	 therefore	 offer	 unique	opportunities	 for	 innovative	 therapies.	 Here,	 we	 have	 shown	 that	 CMTM6,	 a	previously	uncharacterised	protein,	 is	 a	master	 regulator	 of	 PD-L1	 cell	 surface	expression	 across	 various	 cancer	 types.	 CMTM6	 associates	 with	 PD-L1	 at	 the	plasma	 membrane	 and	 in	 recycling	 endosomes	 where	 it	 protects	 PD-L1	 from	being	 targeted	 for	 lysosomal	 degradation.	 CMTM6	 shows	 significant	 specificity	for	 PD-L1	 and	 does	 not	 compromise	 antigen	 presentation	 via	 MHC	 Class	 I	suggesting	 that	 it	 could	 serve	 as	 a	 specific	 therapeutic	 target	 to	 enhance	 anti-tumour	 immunity	 to	 an	 extent	 that	 is	 comparable	 to	 clinically	 used	 anti-PD-1	therapies.	As	existing	immune	checkpoint	therapies	are	not	universally	effective	and	 may	 be	 limited	 by	 toxicities18,	 identifying	 novel	 immunotherapies	 and	combination	 strategies	 is	 a	major	 priority19.	 	 These	 findings	 establish	 CMTM6	and	 its	 regulatory	 pathway	 as	 a	 potential	 new	 therapeutic	 avenue	 to	 enhance	tumour	specific	immunity.		 	
References:	1	 Sharma,	 P.	 &	 Allison,	 J.	 P.	 The	 future	 of	 immune	 checkpoint	 therapy.	
Science	348,	56-61,	(2015).	2	 Boussiotis,	 V.	 A.	 Molecular	 and	 Biochemical	 Aspects	 of	 the	 PD-1	Checkpoint	Pathway.	N	Engl	J	Med	375,	1767-1778,	(2016).	3	 Green,	 M.	 R.	 et	 al.	 Integrative	 analysis	 reveals	 selective	 9p24.1	amplification,	increased	PD-1	ligand	expression,	and	further	induction	via	JAK2	 in	nodular	sclerosing	Hodgkin	 lymphoma	and	primary	mediastinal	large	B-cell	lymphoma.	Blood	116,	3268-3277,	(2010).	4	 Kataoka,	K.	et	al.	Aberrant	PD-L1	expression	through	3'-UTR	disruption	in	multiple	cancers.	Nature	534,	402-406,	(2016).	5	 Morgens,	 D.	 W.	 et	 al.	 Genome-scale	 measurement	 of	 off-target	 activity	using	Cas9	toxicity	in	high-throughput	screens.	Nature	communications	8,	15178,	(2017).	6	 Han,	W.	et	al.	Identification	of	eight	genes	encoding	chemokine-like	factor	superfamily	 members	 1-8	 (CKLFSF1-8)	 by	 in	 silico	 cloning	 and	experimental	validation.	Genomics	81,	609-617,	(2003).	7	 Sanchez-Pulido,	 L.,	 Martin-Belmonte,	 F.,	 Valencia,	 A.	 &	 Alonso,	 M.	 A.	MARVEL:	a	 conserved	domain	 involved	 in	membrane	apposition	events.	
Trends	Biochem	Sci	27,	599-601,	(2002).	8	 Weekes,	 M.	 P.	 et	 al.	 Latency-associated	 degradation	 of	 the	 MRP1	 drug	transporter	during	latent	human	cytomegalovirus	infection.	Science	340,	199-202,	(2013).	9	 Matheson,	N.	J.	et	al.	Cell	Surface	Proteomic	Map	of	HIV	Infection	Reveals	Antagonism	of	Amino	Acid	Metabolism	by	Vpu	and	Nef.	Cell	Host	Microbe	
18,	409-423,	(2015).	10	 Grant,	 B.	 D.	 &	 Donaldson,	 J.	 G.	 Pathways	 and	 mechanisms	 of	 endocytic	recycling.	Nat	Rev	Mol	Cell	Biol	10,	597-608,	(2009).	11	 van	Weert,	A.	W.,	Geuze,	H.	 J.,	Groothuis,	B.	&	Stoorvogel,	W.	Primaquine	interferes	 with	 membrane	 recycling	 from	 endosomes	 to	 the	 plasma	membrane	 through	a	direct	 interaction	with	endosomes	which	does	not	involve	 neutralisation	 of	 endosomal	 pH	 nor	 osmotic	 swelling	 of	endosomes.	Eur	J	Cell	Biol	79,	394-399,	(2000).	12	 Arjonen,	A.,	Alanko,	J.,	Veltel,	S.	&	Ivaska,	J.	Distinct	recycling	of	active	and	inactive	beta1	integrins.	Traffic	13,	610-625,	(2012).	13	 Tumeh,	P.	C.	et	al.	PD-1	blockade	induces	responses	by	inhibiting	adaptive	immune	resistance.	Nature	515,	568-571,	(2014).	14	 Homet	Moreno,	B.,	Parisi,	G.,	Robert,	L.	&	Ribas,	A.	Anti-PD-1	 therapy	 in	melanoma.	Semin	Oncol	42,	466-473,	(2015).	15	 Li,	 C.	 W.	 et	 al.	 Glycosylation	 and	 stabilization	 of	 programmed	 death	ligand-1	 suppresses	 T-cell	 activity.	 Nature	 communications	 7,	 12632,	(2016).	16	 Behren,	 A.	 et	 al.	 The	 Ludwig	 institute	 for	 cancer	 research	 Melbourne	melanoma	 cell	 line	 panel.	 Pigment	 Cell	 Melanoma	 Res	 26,	 597-600,	(2013).	17	 Woods,	 K.	 &	 Cebon,	 J.	 Tumor-specific	 T-cell	 help	 is	 associated	 with	improved	survival	in	melanoma.	Clin	Cancer	Res	19,	4021-4023,	(2013).	
18	 Boutros,	C.	et	al.	 Safety	profiles	of	anti-CTLA-4	and	anti-PD-1	antibodies	alone	and	in	combination.	Nat	Rev	Clin	Oncol	13,	473-486,	(2016).	19	 Mahoney,	 K.	 M.,	 Rennert,	 P.	 D.	 &	 Freeman,	 G.	 J.	 Combination	 cancer	immunotherapy	 and	 new	 immunomodulatory	 targets.	 Nat	 Rev	 Drug	
Discov	14,	561-584,	(2015).			 	
ACKNOWLEDGMENTS		M.L.B.	 is	 supported	 by	 a	 Cancer	 Research	 UK	 Fellowship,	 Addenbrooke’s	Charitable	 Trust	 award	 and	 NIHR	 fellowship.	 M.A.D.	 is	 supported	 by	 a	 Senior	Leukaemia	Foundation	Australia	Fellowship	and	work	in	the	Dawson	laboratory	is	 supported	 by	 the	 NHMRC	 (Grants	 1085015,	 1106444,	 1106447)	 Cancer	Council	 Victoria	 and	 Leukaemia	 Foundation	 Australia.	 P.J.L	 is	 supported	 by	 a	Wellcome	 Trust	 PRF	 (101835/Z/13/Z)	 and	 work	 in	 the	 Lehner	 laboratory	 is	supported	by	NHSBT,	NIHR	Cambridge	BRC,	a	Wellcome	Trust	Strategic	Award	to	CIMR,	and	the	Addenbrooke’s	Charitable	Trust.	
AUTHOR	CONTRIBUTIONS	M.L.B,	 P.J.L.	 and	M.A.D.	 designed	 the	 research	 and	 interpreted	 data.	M.A.D	 and	M.L.B	wrote	the	manuscript	with	assistance	from	P.J.L,	Y-C.C	and	E.Y.N.L.	M.L.B,	C.E.S,	Y-C.C,	E.Y.N.L,	C.C.B,	S.S,	and	O.G.	performed	experiments	and	analyzed	data	directly	supervised	by	M.A.D.	M.L.B	performed	the	CRISPR	screen	assisted	by	S.B.	and	 J.C.W	 performed	 the	 plasma	membrane	 profiling	 supervised	 by	 P.J.L.	 K.W.	and	A.B.	performed	T-cell	assays	supervised	by	J.C.	P.A.B	and	M.A.H.	performed	the	 mouse	 experiments.	 D.M.	 and	 M.C.B.	 designed	 and	 generated	 the	 CRISPR	sgRNA	 library.	 P.J.N,	 P.K.D,	 S-J.D,	 I.V	 and	 J.A.T	 provided	 critical	 reagents	 and	aided	in	manuscript	preparation.		
AUTHOR	INFORMATION	STATEMENT	Reprints	and	permissions	information	is	available	at	www.nature.com/reprints.	The	 authors	 have	 no	 competing	 interests	 to	 declare.	 Correspondence	 and	requests	for	materials	should	be	addressed	to	mark.dawson@petermac.org.			 	
Figure	1:	CMTM6	 is	a	principal	 regulator	of	PD-L1	expression	 in	multiple	
tumour	types	
a.	A	genome-wide	CRISPR/Cas9	screen	identifies	genes	essential	for	cell	surface	PD-L1	 expression.	 BxPC-3	 pancreatic	 cancer	 cells	 expressing	 Cas9	 were	mutagenised	with	a	pooled	lentiviral	sgRNA	library	and	PD-L1	low	cells	enriched	by	FACs	sorting	b&c.	Significant	hits	from	screens	in	cells	pre-treated	with	IFN-γ	before	 sorting	 (B)	 and	 non-IFN-γ	 treated	 cells	 (C).	 Dotted	 line	 indicates	Bonferroni-corrected	 significance	 threshold.	 d.	 Immunoblot	 in	 MDA-MB-231	cells	expressing	Cas9	and	sgRNAs	 targeting	either	CMTM6	or	PD-L1.	e.	 Surface	PD-L1	 in	 IFN-γ-treated	 cells	 transduced	 with	 CMTM6-specific	 sgRNAs	 versus	parental	Cas9	expressing	cells.	See	Extended	Data	Fig.	3	for	full	dataset.	f.	PD-L1	expression	in	CMTM6	knockout	MDA-MB-231	cells	±	CMTM6	cDNA	analysed	by	flow	 cytometry	 and	 immunoblot.	 Representative	 of	 3	 experiments.	g.	 qRT-PCR	analysis	in	control	and	CMTM6-depleted	cells	treated	±	500IU/ml	IFN-γ	for	48h.	2	biological	replicates	(mean,	s.e.m.).		
Figure	2:	CMTM6	shows	functional	specificity	for	PD-L1	
a.	PD-L1	is	readily	detected	in	association	with	CMTM6.	Immunoprecipitation	of	CMTM6	 (left	 panel)	 or	 PD-L1	 (right	 panel)	 from	 	 digitonin	 lysates	 of	 IFN-γ	treated	 MDA-MB-231	 cells.	 Analysis	 by	 immunoblot.	 Lysate	 =	 5%	 of	 input.	Experiments	performed	twice.	b.	Interaction	of	CMTM6	with	PD-L1	is	detergent-sensitive.	 Cells	were	 lysed	 in	 1%	digitonin	 (Dig)	 and	 adjusted	 to	 the	 indicated	detergent	 concentrations	 prior	 to	 immunoprecipitation	 of	 PD-L1.	 Experiment	performed	twice.	c.	PD-L1	and	CMTM6	co-localise	at	the	plasma	membrane.	PD-L1	knockout,	CMTM6	knockout	and	parental	MDA-MB-231	Cas9	cells	were	fixed,	immunostained	 for	 PD-L1	 and	 CMTM6	 and	 analysed	 by	 confocal	 microscopy.	Scale	bar:	10µm.	d&e.	Quantitative	plasma	membrane	profiling.	d.	Experimental	workflow	e.	Scatterplots	display	pairwise	comparisons	between	parental	MDA-MB-231	Cas9,	CMTM6	sgRNA1	and	CMTM6	sgRNA2-expressing	cells.	Experiment	performed	 in	 triplicate.	 q-values	 determined	 using	 LIMMA	 with	 Benjamini-Hochberg	adjustment	for	multiple	testing.		
Figure	3:	CMTM6	is	required	for	efficient	endocytic	recycling	of	PD-L1	
a.	 IFN-γ	 treated	 CMTM6	knockout	 or	 parental	WM-852	Cas9	 cells	were	 pulse-labelled	 with	 35S-methionine/cysteine	 for	 30	 min,	 chased	 at	 370C	 and	 PD-L1	immunoprecipitated	from	detergent	lysates	at	the	indicated	times.	Eluates	were	split	 and	 incubated	 ±	 Endoglycosidase-H.	 Scans	 quantitated	 in	 ImageJ.	Representative	 of	 3	 experiments.	 b-e.	 Cell	 surface	 PD-L1	 is	 targeted	 for	degradation	 in	 the	absence	of	CMTM6.	 	b&c.	 IFN-γ	 treated	WM-852	cells	were	treated	as	described	(b).	Representative	of	six	experiments	(see	Extended	Data	Fig.	 7a	 &	 9a).	d&e.	 	 Cell	 surface	 IP	 (CS-IP).	 IFN-γ	 treated	WM-852	 cells	 were	treated	as	described	(d)	and	PD-L1	immunoprecipites	analysed	by	immunoblot.	
f.	 CMTM6	and	PD-L1	are	 identified	 in	 recycling	endosomes.	MDA-MB-231	cells	were	fixed	and	immunostained	for	CMTM6	(large	panel)	or	PD-L1	(right	panel)	plus	 markers	 of	 the	 ER	 (calnexin	 (CANX)),	 Golgi	 (GM130	 and	 TGN46),	 early	endosome	 (EEA1),	 late	 endosome/lysosome	 (LAMP1)	 or	 recycling	 endosome	(RAB11	and	transferrin	receptor	(TFRC)).	Scale	bar:	10µm.	g&h.	PD-L1	recycling	is	 impaired	 in	 the	 absence	 of	 CMTM6.	 g.	 IFN-γ	 treated	 WM-852	 cells	 were	labelled	with	an	unconjugated	PD-L1-specific	antibody	before	incubation	at	370C	±	primaquine	(described	in	Extended	Data	Fig.	8a).		Remaining	antibody-labelled	surface	PD-L1	was	detected	with	an	AF647-conjugated	anti-mouse	antibody	and	analysed	 by	 flow	 cytometry.	h.	 PD-L1	 recycling	 in	 IFN-γ-treated	WM-852	 cells	(assay	 described	 in	 Extended	 Data	 Fig.	 8c).	 Graph	 shows	 the	 proportion	 of	internalised	 antibody-labelled	 PD-L1	 recycled	 at	 each	 time-point.	 	 g&h.	Mean	and	s.e.m.	from	3	experiments.				
Figure	4.	CMTM6	regulates	tumour-specific	T	cell	activity	by	regulating	PD-
L1	levels	
a-c.	 CMTM6	 protects	 PD-L1	 from	 lysosome-mediated	 degradation.	 a.35S-methionine/cysteine	pulse-chase	in	IFN-γ	treated	WM-852	cells	(as	in	Figure	3a)	±	50nM	Concanamycin-A	(ConA)	as	 indicated	 	b.	Quantitation	of	a	 in	 ImageJ.	c.	Cell-surface	IP	in	CMTM6	knockout	cells	(see	Figure	3d/e).	Incubation	at	370C	±	50nM	 ConA	 or	 50µM	 Chloroquine	 d.	 MDA-MB-231	 cells	 expressing	 CMTM6-targeting	 or	 control	 shRNAs	 were	 incubated	 ±	 50nM	 ConA	 for	 16	 h	 before	analysis	by	immunoblot	e.	CMTM6	knockout	MDA-MB-231	cells	were	fixed	and	
immunostained	 for	 PD-L1	 following	 16	 h	 incubation	 ±	 ConA.	 Scale	 bar:	 10µm.		
f&g.	 CMTM6	 regulates	 the	 anti-tumour	 activity	 of	 antigen-specific	 CTLs	 f.	Intracellular	staining	for	perforin	or	TNF-α	in	NY-ESO-192-100	CTLs	following	24	h	co-culture	with	CMTM6	sgRNA,	PD-L1	sgRNA	or	control	vector	transduced	LM-MEL-53	Cas9	cells	g.	IFN-γ	and	Il-2	levels	in	supernatants	from	3	day	co-cultures	of	 NY-ESO-192-100	 CTLs	 and	 LM-MEL-53	 cells	 f&g.	 Where	 indicated,	 10µg/ml	nivolumab	(anti-PD-1)	was	added	to	the	co-culture.	Results	are	triplicates	(mean	+	 s.e.m.)	 *	p	<	0.05,	 **	p	<	0.01,	unpaired	 two-tailed	 t-test.	h&i.	 C57BL/6	mice	injected	 subcutaneously	 with	 105	 B16-OVA	 cells	 transduced	 with	 a	 CMTM6-targeting	 or	 control	 shRNA.	 I.	 Kaplan-Meier	 survival	 curve	 shows	 pooled	 data	from	 3	 experiments	 (23/24	 mice	 per	 group).	 	 Survival	 endpoint	 =	 tumour	>100mm2.	Mantel-Cox	test.	j.	Growth	of	CMTM6-deficient	and	control	tumours,	9	mice	per	group.	Black	line	indicates	mean	tumour	size.	Data	from	all	experiments	shown	 in	Extended	Data	Fig.	10.	 	 j.	 	CMTM6	(orange)	binds	PD-L1	(green)	and	maintains	its	cell	surface	expression.	In	the	absence	of	CMTM6,	endocytosed	PD-L1	is	rerouted	for	lysosomal	degradation.		
	
Methods	
Cell	Culture	WM-852	 cells	 were	 obtained	 from	 the	 European	 Searchable	 Tumour	 Line	Database	 (ESTDAB)	 cell	 line	 repository	and	BxPC-3	 cells	were	a	kind	gift	 from	Yaohe	Wang	(Barts	Cancer	Institute,	London).	HEK	293ET	cells,	were	a	gift	from	Dr.	Felix	Randow	(MRC-LMB,	Cambridge,	UK).	HCC-827,	MDA-MB-231	and	A375	were	obtained	from	ATCC.	The	patient-derived	melanoma	cell	lines	LM-MEL-53	and	 LM-MEL-44	were	 established	 and	 characterised	 as	 previously	 described22.	Cells	were	cultured	 in	RPMI-1640	or	DMEM	(BxPC-3,	HEK-293ET	and	B16F10-OVA)	 supplemented	 with	 2	 mM	 Glutamax,	 100	 IU/ml	 Penicillin,	 100	 μg/ml	Streptomycin	and	10	%	heat-inactivated	fetal	calf	serum.			Cell	 lines	were	authenticated	by	STR	profiling	 through	 the	Victorian	Centre	 for	Functional	Genomics.		Most	recent	authentication	1st	March	2017.	Cell	lines	were	
regularly	tested	and	verified	to	be	mycoplasma	negative	by	PCR	analysis	by	the	Victorian	Infectious	Diseases	References	Lab	(Melbourne,	Victoria).	
CRISPR/Cas9-mediated	gene	disruption.		sgRNA	oligonucleotides	(Sigma-Aldrich)	were	phosphorylated	and	annealed	and	cloned	 into	 lentiviral	 expression	 vectors,	 pKLV-U6gRNA(BbsI)-PGKpuro2ABFP	(Addgene	 #50946,	 deposited	 by	 Dr.	 Kosuke	 Yusa),	 or	 FgH1tUTG	 (Addgene	#70183,	 a	 gift	 from	 Marco	 Herold)	 for	 inducible	 sgRNA	 expression.	 	 For	CRISPR/Cas9-mediated	 gene	 disruption,	 cells	 were	 first	 transduced	 with	 the	Cas9	 expression	 vector	 pHRSIN-PSFFV-Cas9-PPGK-Blasticidin,	 selected	 with	blasticidin,	and	then	subsequently	transduced	with	a	lentiviral	sgRNA	expression	vector.		For	transient	sgRNA	expression	using	FgH1tUTG,	cells	were	treated	with	Doxycyline	 for	 1	 week.	 	 CMTM6	 knockout	 and	 PD-L1	 knockout	 clones	 were	isolated	 by	 single	 cell	 dilution	 cloning	 from	 polyclonal	 sgRNA-transduced	populations.		Knockout	clones	were	identified	by	flow	cytometry	analysis	for	cell	surface	PD-L1	followed	by	immunoblot	for	CMTM6	and	PD-L1.		
Lentiviral	production	and	transduction		Lentivirus	 was	 produced	 by	 triple	 transfection	 of	 HEK-293ET	 cells	 with	 a	lentiviral	transfer	vector,	and	the	packaging	plasmids	pCMVΔR8.91	and	pMD.G	at	a	 0.5:0.35:0.15	 ratio.	 Transfection	 was	 performed	 using	 JetPEI	 reagent	 as	recommended	 by	 the	manufacturer.	 The	 viral	 supernatant	 was	 collected	 48	 h	following	transfection,	filtered	through	a	0.45	μm	filter,	and	added	to	target	cells.			For	 lentiviral	expression	of	shRNAs,	shRNAs	targeting	CMTM6	or	non-targeting	control	 shRNAs	were	 cloned	 into	 the	 pHR-SIREN	 vector,	which	 co-expresses	 a	GFP	selection	marker,	via	BamHI	and	EcoRI.		
CRISPR	sgRNA	Library	A	 10-sgRNA-per-gene	 CRISPR/Cas9	 deletion	 library	was	 designed	 to	 target	 all	~20,500	protein-coding	human	genes.		The	library	contained	two	distinct	classes	
of	negative	control	gRNAs:	non-targeting	control	sgRNA	with	no	binding	sites	in	the	 genome	 and	 safe-targeting	 sgRNA	 targeting	 genomic	 locations	 with	 no	annotated	function.		Further	details	are	described	in	Morgens	DW	et	al7.		
CRISPR	screen	BxPC-3	cells	were	transduced	with	a	lentiviral	vector	encoding	Cas9	and	selected	with	 blasticidin.	 108	 cells	 BxPC-3	 Cas9	 cells	 were	 infected	 with	 the	 pooled	lentiviral	 genome-wide	 sgRNA	 library	 at	 a	 multiplicity	 of	 infection	 of	 0.3	 and	selected	with	1µg/ml	puromycin	for	72	h,	commencing	48	h	after	transduction.		Rare	PD-L1	low	cells	were	enriched	by	two	rounds	of	FACS	sorting	at	day	7	and	day	 15	 following	 transduction	 with	 the	 sgRNA	 library.	 For	 the	 sorts,	 cells	 (at	least	108	for	the	first	sort)	were	pre-treated	with	or	without	500IU/ml	IFN-γ	for	48	h,	harvested	with	 trypsin,	stained	with	APC-conjugated	anti-PD-L1	antibody	(MIH1,	eBioscience)	for	15	min	on	ice	and	washed	with	PBS	prior	to	sorting	for	mCherry	positive	(sgRNA	expressing)	PD-L1	low	cells	on	a	BD	Influx	cell	sorter.		Genomic	DNA	was	extracted	(Puregene	Core	Kit	A,	Qiagen)	from	both	the	sorted	cells	and	an	unselected	pool	of	mutagenised	cells	grown	for	the	same	amount	of	time.	 sgRNA	sequences	were	amplified	by	 two	 rounds	of	PCR,	with	 the	 second	round	 primers	 containing	 adaptors	 for	 Illumina	 sequencing.	 	 The	 resulting	libraries	 were	 sequenced	 with	 single-end	 50	 bp	 reads	 on	 aHiSeq2500.	 The	sequence	 reads	 were	 trimmed	 to	 remove	 the	 constant	 portion	 of	 the	 sgRNA	sequences	 with	 fastx	 clipper	 (http://hannonlab.cshl.edu/fastx_toolkit/),	 then	mapped	 to	 the	reference	sgRNA	 library	with	bowtie2.	After	 filtering	 to	 remove	multi-aligning	 reads,	 the	 read	counts	were	computed	 for	each	sgRNA.	The	RSA	algorithm	 was	 used	 to	 rank	 the	 genes	 for	 which	 targeting	 sgRNA	 were	significantly	 enriched	 in	 the	 sorted	 populations	 compared	 to	 the	 control	unsorted	populations	grown	in	parallel.	The	p-value	cut-off	for	significance	was	adjusted	to	account	for	multiple-testing	using	the	bonferroni	correction.			
Antibodies	Immunofluorescence:	 mouse	 α-EEA1	 (1G11,	 eBioscience),	 mouse	 α-PD-L1	
(MIH1,	 eBioscience),	 rabbit	 α-PD-L1	 (EPFR19759,	 Abcam),	 mouse	 α-LAMP1	(H4A4,	 eBioscience),	 mouse	 α-Calnexin	 (AF18,	 Abcam),	 mouse	 α-GM130	(169276,	Abcam),	mouse	α-TGN46	(2F7.1,	Abcam),	mouse	α-Rab11	(47/Rab11,	BD	 Transduction	 Laboratories),	 mouse	 α-TfR	 (236-15375,	 Thermo-Fisher),	rabbit	α-CMTM6	(HPA026980,	Sigma-Aldrich).		Flow	 Cytometry:	 FITC	mouse	 IgG2a	 κ	 isotype	 control	 (MOPC-173,	 Biolegend),	APC	 mouse	 IgG2b	 κ	 isotype	 control	 (MPC-11,	 Biolegend),	 APC	 mouse	 IgG1	 κ	isotype	 control	 (MOPC-21),	 APC	 mouse	 α-PD-L1	 (29E.2A3,	 Biolegend),	 APC	mouse	α-PD-L1	 (MIH1,	 eBioscience),	 Alexa	 Fluor	 488	 rabbit	 α-PD-L1	 (Abcam),	APC	mouse	 α-HLA-ABC	 (W6/32),	 Alexa	 Fluor	 488	mouse	 α-HLA-ABC	 (W6/32,	Biolegend),	FITC	mouse	α-CD8	(HIT8a,	BD	Pharmingen),	PE-Cy7	mouse	α-TNFα	(MAb11,	 eBioscience),	 APC	 mouse	 α-PD-1	 (J105,	 eBioscience),	 PerCp-Cy5.5	mouse	α-Perforin	(B-D48,	Biolegend).	Immunoprecipitation/Immunoblotting:	 goat	 anti-PDL1	 (AF156,	 R&D	 Systems),	rabbit	α-PD-L1	(E1L3N,	Cell	Signalling	Technology),	mouse	α-PD-L1	(405.9A11,	Cell	 Signalling	 Technology),	 mouse	 α-PD-L1	 (MIH1,	 eBioScience),	 rabbit	 α-CMTM6	(Sigma-Aldrich,	HPA026980).	
	
Immunoblotting	and	Immunoprecipitation	For	 immunoblotting	 cells	 were	 lysed	 either	 in	 1%	 Triton	 X-100	 in	 TBS	 pH7.6	with	Roche	complete	protease	inhibitor	for	30	min	on	ice	followed	by	pelleting	of	insoluble	material	 by	 centrifugation,	 or	 in	 1%	 SDS	 in	 100mM	 Tris-HCl	 pH	 8.0	plus	Benzonase	 (Sigma)	at	 room	 temperature.	 	Lysates	were	heated	 to	70°C	 in	SDS	 sample	 buffer	 with	 50mM	 DTT	 for	 10	 min,	 separated	 by	 SDS-PAGE,	 and	transferred	 to	 PVDF	 membrane	 (Millipore).	 Membranes	 were	 blocked	 in	 5%	milk	in	TBS	+	0.1%	Tween-20,	probed	with	the	indicated	antibodies,	and	reactive	bands	visualised	using	West	Pico	(Thermo	Fisher	Scientific).		For	 co-immunoprecipitation	 experiments,	 cells	were	 lysed	 in	 1%	Digitonin	 for	30	min	on	ice.	Post-nuclear	supernatants	were	adjusted	to	0.5%	Digitonin	or	to	
the	 detergent	 concentration	 indicated	 in	 the	 figures,	 incubated	 with	 primary	antibody	for	1	–	4	h,	followed	by	addition	of	protein	A-	or	protein	G-Dynabeads	and	 incubation	 for	 a	 further	 2	 h	 at	 4°C.	 	 After	 four	washes	 in	 0.2%	Digitonin,	samples	were	eluted	in	SDS	sample	buffer	with	50mM	DTT	for	10	min	at	70°C,	separated	by	SDS-PAGE	and	immunoblotted	as	described.	For	immunoprecipitation	of	cell	surface	PD-L1	(CS-IP),	live	cells	were	incubated	with	anti-PD-L1	antibody	(MIH1,	10µg/ml)	for	60	min	on	ice.	After	3	washes	in	ice-cold	 PBS	 to	 remove	 unbound	 antibody,	 cells	 were	 resuspended	 in	prewarmed	 complete	medium	 (RPMI/10%	FCS)	 and	 incubated	 at	 370C	 for	 the	indicated	times.	Cells	were	placed	back	on	ice,	washed	once	in	PBS	and	lysed	in	1%	 NP-40/TBS	 pH7.6	 plus	 Roche	 complete	 protease	 inhibitor.	 Post-nuclear	supernatants	were	incubated	with	protein	G-Dynabeads	for	3	h	at	4°C	to	capture	antibody-bound	PD-L1.	 	After	four	washes	in	0.2%	NP-40,	samples	were	eluted	in	SDS	sample	buffer	with	50mM	DTT	for	10	min	at	70°C,	separated	by	SDS-PAGE	and	immunoblotted	as	described.		
Metabolic	Labelling	and	Pulse-Chase	
Cells were starved for 20 min in methionine-free, cysteine-free medium, labelled with 
[35S]methionine/[35S]cysteine) (Perkin-Elmer) for 30 min and then chased in medium 
containing excess cold methionine and cysteine (Sigma-Aldrich) at 370C. Samples 
taken at the indicated time-points were lysed in 1% NP-40/TBS pH 7.6 with Roche 
complete protease inhibitor and 10mM iodoacetamide (IAA). Post-nuclear 
supernatants were pre-cleared with a combination of IgG-sepharose and Protein G 
Dynabeads for 1 to 2 h on a rotator at 40C, and then incubated (rotating) with a PD-
L1-specific antibody (AF156, R & D systems) for 1 h before adding Protein G 
Dynabeads for a further 2 h at 40C.  After 4 washes in 0.2% lysis buffer, samples were 
eluted in SDS sample buffer for 10 min at 70°C. Where indicated, eluates were 
treated with Endoglycosidase H (New England Biolabs) according to the 
manufacturer’s instructions before separation by SDS-PAGE. Gels were fixed, dried 
at 80°C for 2 h and processed for autoradiography. Phosphor screens were exposed to 
the radiolabelled proteins in fixed, dried gels overnight. Screens were scanned using a 
TYPHOON scanner and bands quantified using ImageJ.  	
Plasma	Membrane	Profiling	by	Mass	Spectrometry	Plasma	 membrane	 profiling	 was	 performed	 as	 previously	 with	 minor	modifications.	MDA-MB231	cells	expressing	either	Cas9	alone	or	Cas9	plus	one	of	 two	 sgRNAs	 targeting	CMTM6	were	 cultured	 to	~80%	confluence	 (3x	14cm	dishes	each).	Cells	were	washed	 in	PBS	before	biotinylation	of	 the	cell	 surface,	washing	and	harvesting	by	scraping.	Cells	were	lysed	in	1%	Triton	X-100	in	TBS	pH8	with	protease	inhibitors	(Complete	EDTA-free,	Roche)	and	incubated	at	4°C	for	 30	 min	 with	 end-over-end	 agitation.	 Following	 centrifugation	 (10,000	 x	 g	10min),	 supernatants	 were	 applied	 to	 50µL	 of	 High-Capacity	 Streptavidin-agarose	resin	(Thermo	Fisher	Scientific)	and	incubated	at	4	°C	for	2	h.		Samples	were	applied	to	500µL	fritted	microcolumns	(Snap-Cap,	Thermo	Fisher	Scientifc)	and	 washed	 using	 a	 vacuum	manifold	 with	 20x400µL	 Lysis	 buffer,	 20x400µL	0.5%	SDS	in	PBS	a	10x400µL	6M	urea	in	50mM	TEAB	buffer	(pH8).	Beads	were	resuspended	 in	 400µL	 urea	 wash	 buffer	 containing	 10mM	 TCEP	 and	 10mM	Iodoacetamide	 and	 incubated	 for	 30	 min	 in	 the	 dark	 at	 room	 temperature	 to	effect	 reduction	 and	 alkylation	 of	 cysteines.	 Following	 10x400µL	 washes	 with	urea	wash	buffer	and	5x400µL	washes	with	50mM	TEAB,	beads	were	recovered	into	 LoBind	 Eppendorf	 tubes,spun	 briefly	 and	 supernatant	 removed	 before	resuspending	 in	 50µL	 of	 50mM	 TEAB	 containing	 0.5µg	 trypsin	 (Proteomics	Grade,	 Thermo	 Fisher).	 Samples	 were	 incubated	 at	 37°C	 for	 8	 h	 in	 a	 Thermo	mixer	 C	 at	 1200rpm.	 Subsequently	 samples	were	 recovered	 from	 streptavidin	beads	and	the	beads	washed	once	with	50µL	50mM	TEAB.	Samples	were	dried	in	a	vacuum	centrifuge	and	resuspended	in	20µL	50mM	TEAB.		TMT	Labelling	To	each	 tube	0.2µg	of	a	unique	TMT	 label	 for	each	sample	was	added	 in	8.5µL	acetonitrile	and	incubated	for	1	h	at	room	temperature.	Labels	were	as	follows.	Control:	 126,	 127N,	 127C.	 sgRNA	 1:	 128N,	 128C,	 129N.	 sgRNA	 2	 129N,	 130N,	
130C.	TMT	reactions	were	quenched	by	addition	of	3µL	of	200mM	ammonium	formate,	pooled	and	dried	in	a	vacuum	centrifuge.	The	sample	was	resuspended	in	800µL	0.1%	TFA	and	acidified	to	~pH2	with	formic	acids	before	performing	a	C18-SPE	 cleanup	 using	 a	 Sep-Pak	 cartridge	 (Waters)	 attached	 to	 a	 vacuum	manifold.	C18	Eluate	was	dried	in	a	vacuum	centrifuge	and	resuspended	in	40µL	200mM	ammonium	formate,	pH10.		High	pH	Reversed	Phase	Fractionation	Sample	was	injected	onto	an	Ultimate	3000	RSLC	UHPLC	system	(Thermo	Fisher	Scientific)	equipped	with	a	2.1	i.d	x25cm,	1.7µm	particle	Kinetix	Evo	C18	column	(Phenomenex).	 Mobile	 phase	 consisted	 of	 A:	 3%	 ACN,	 B:	 ACN	 and	 C:	 200mM	ammonium	 formate	pH	10.	 Isocratic	 conditions	were	90%	A/10%C	and	C	was	maintained	 at	 10%	 throughout	 the	 gradient	 elution.	 Separations	 were	 carried	out	at	450C.	After	loading	at	200µL/min	for	5	min	and	ramping	the	flow	rate	to	400µL/min	over	5	min	the	gradient	elution	proceed	as	follows:	0-19%	B	over	10	min	 (curve	 3),	 19-34%B	 over	 14.25	 min	 (curve	 5),	 34-50%B	 over	 8.75	 min	(curve	5),	followed	by	a	10	min	wash	at	90%	B.	UV	absorbance	was	monitored	at	280nm	 and	 15s	 fractions	 were	 collected	 into	 96	 well	 microplates	 using	 the	integrated	 fraction	 collector.	 Peptide	 containing	 fractions	 were	 then	orthogonally	recombined	into	12	fractions	and	dried	in	a	vacuum	centrifuge	and	resuspended	in	10µL	5%	DMSO	0.5%	TFA	for	analysis.		LC-MS	analysis	All	 samples	were	 injected	 onto	 an	 Ultimate	 3000	 RSLC	 nano	UHPLC	 equipped	with	 a	 300µm	 i.d.	 x	 5mm	 Acclaim	 PepMap	 µ-Precolumn	 (Thermo	 Fisher	Scientific)	and	a	75µm	i.d.	x75cm	2.1µm	particle	Acclaim	PepMap	RSLC	analytical	column.	 Loading	 solvent	 was	 0.1%	 TFA,	 analytical	 solvent	 A:	 0.1%	 FA	 and	 B:	ACN+0.1%	FA.	All	separations	were	performedat	550C.	Samples	were	 loaded	at	10µL/min	for	5	min	in	loading	solvent	before	beginning	the	analytical	gradient.	For	High	 pH	RP	 fractions	 a	 gradient	 of	 3-5.6%B	 over	 4	min,	 5.6	 –	 32%B	 over	162min,	 followed	 by	 a	 5	 min	 wash	 at	 80%B,a	 5	 minute	 wash	 at	 90%B	 and	equilibration	 at	 3%B	 for	5min.	 For	 IP	 samples	 a	 linear	 gradient	 from	3-5.6%B	over	8min	and	5.6-32%B	over	72min,	followed	by	a	5	minute	wash	at	80%B	and	
a	5	minute	wash	at	90%B	and	equilibration	at	3%B	for	5	min.	A	blank	injection	was	run	between	each	sample.		Data	Processing	All	Raw	files	were	searched	by	Mascot	within	Proteome	Discoverer	2.1	(Thermo	Fisher	 Scientific)	 against	 the	 Swissprot	 Human	 database	 (11/12/2016)	 and	 a	database	 of	 common	 contaminants.	 For	 TMT	 labelled	 samples	 the	 search	parameters	were	as	 follows.	Enzyme:	Trypsin.	MS1	tol:	10ppm.	MS2	tol:	0.6Da.	Fixed	 modifications:	 Carbamidomethyl	 Cysteine,	 TMT	 peptide	 N	 termini	 and	Lysine.	Variable	modification	oxidised	methionine.	MS3	reporter	ion	tol:	20ppm,	most	confident	centroid.	Mascot	Percolator	was	used	to	calculate	PSM	FDR.		Search	results	were	further	processed	and	filtered	as	follows:	Peptides	below	a	percolator	FDR	of	0.01%	and	proteins	below	the	0.01%	protein	FDR	(calculated	from	a	built	in	decoy	database	search)	were	rejected.		Protein	groups	were	then	generated	using	the	strict	parsimony	principle.	Peptides	both	unique	and	razor	with	a	co-isolation	threshold	of	50	and	an	average	s/n	threshold	of	10	were	used	for	 quantification	 and	 a	 normalisation	 of	 these	 values	 on	 the	 total	 peptide	amount	 in	 each	 channel	was	 applied.	 Instances	where	 a	protein	was	 identified	but	 not	 quantified	 in	 all	 channels	were	 rejected	 form	 further	 analysis.	Manual	interpretation	of	the	data	did	not	reveal	any	protein	conspicuously	absent	from	any	sample	set.	Processed	data	were	analysed	in	R	using	a	custom	script	to	apply	the	 moderated	 t-test	 LIMMA	 including	 Benjamini-Hochberg	 correction	 for	multiple	hypotheses.	Dataset	2	holds	all	data	from	the	experiment.			
Co-Immunoprecipitation	and	Mass	Spectrometry	IFN-γ	 treated	 MDA-MB-231	 cells,	 and	 CMTM6	 knockout	 cells	 as	 a	 negative	control,	were	lysed	in	1%	Digitonin	with	Roche	complete	protease	inhibitor	and	10mM	 iodacetamide.	 Post-nuclear	 supernatants	 were	 adjusted	 to	 0.5%		Digitonin	 and	 pre-cleared	 with	 protein	 A-Dynabeads	 for	 2	 h,	 incubated	 with	rabbit	 anti-CMTM6	primary	 antibody	 (Sigma,	HPA026980)	 for	2	h	 followed	by	
addition	of	protein	A-Dynabeads	for	a	further	2	h	at	4°C.	Following	four	washes	in	0.2%	Digitonin,	samples	were	eluted	in	SDS	sample	buffer	with	50mM	DTT	at	70°C	 for	 10	 min.	 	 Eluates	 were	 run	 ~1cm	 into	 NuPage	 4-12%	 BIS-TRIS	polyacrylamide	 gels	 (Invitrogen),	 stained	 with	 .	 Coomassie	 (Simply	 Stain,	Invitrogen)	 and	 cut	 into	 ~1mm	 square	 pieces.	 Gel	 pieces	 were	 destained	overnight	in	50%	ACN,	shrunk	in	100%	ACN	and	rehydrated	in	50mM	TEAB	(pH	8.5),	10mM	TCEP,	10mM	Iodoacetamide	and	incubated	at	room	temperature	for	30	min	 in	the	dark.	Gel	pieces	were	shrunk	 in	ACN,	rehydrated	 in	50mM	TEAB	and	 finally	 shrunk	 in	ACN	and	dried	briefly	 in	 a	 vacuum	centrifuge.	Gel	 pieces	were	 incubated	 in	50mM	TEAB	with	10ng/µL	 trypsin	on	 ice	 for	30	min	before	50mM	 TEAB.	 incubation	 overnight	 at	 37°C	 in	 50mM	 TEAB.	 Peptides	 were	recovered	by	sequential	shrink/rehydrate	cycles	of	ACN,	5%FA,	ACN	and	dried	in	 a	 vacuum	 centrifuge.	 Prior	 to	 analysis	 they	 were	 resuspended	 in	 10µL	 5%	DMSO	0.5%	TFA.	Samples	were	acquired	on	the	same	platform	as	for	the	plasma	membrane	profiling	experiments.		A	threshold	of	0.01%	PSM	and	0.01%	protein	FDR	 was	 used	 as	 a	 cut-off	 for	 identification.	 	 To	 identify	 specific	 interaction	partners	 of	 CMTM6,	 the	 data	were	 filtered	 to	 remove	 proteins	 also	 present	 in		control	immunoprecipitations	fromCMTM6	KO	cells	(Dataset	1).		
Flow	cytometry		Cells	were	washed	in	PBS	and	stained	for	cell	surface	PD-L1	or	MHC	class	I	on	ice	for	20	min	in	PBS	plus	2%	FCS.			After	washing	in	PBS	samples	were	analysed	on	a	BD	LSR	Fortessa	and	analysed	in	FlowJo.		
Endocytosis	and	Recycling	Assays	Assays	 were	 performed	 using	 three	 different	 WM-852	 melanoma	 CMTM6	knockout	clones	(shown	in	extended	Data	Fig.	5A)	and	parental	CAs9-expressing	cells.	 	All	cells	were	pre-treated	with	IFNγ	500IU/ml	for	18-24h	before	starting	the	assays.	
i)	Internalisation	Assay	Cells	were	 placed	 on	 ice	 and	washed	 once	 in	 RPMI	 /	 5%	 FCS	 /	 30mM	HEPES	
(used	 for	 all	 staining	 and	 wash	 steps).	 Cell	 surface	 PDL1	 was	 labelled	 with	unconjugated	anti-PDL1	(29E.2A3,	Biolegend)	for	1	h	on	ice	and	washed	twice	to	remove	unbound	antibody.	Cells	were	resuspended	in	RPMI	medium	on	ice	and	a	baseline	 sample	 removed	 and	 kept	 on	 ice.	 Cells	 were	 incubated	 at	 370C	 in	 a	water-bath,	in	the	presence	of	300	µM	primaquine	where	indicated,	and	samples	were	removed	at	the	indicated	times	and	immediately	diluted	in	ice-cold	PBS	to	stop	further	endocytosis.	Cells	were	washed	twice,	and	remaining	surface	bound	anti-PD-L1	 antibody	 stained	 with	 Alexa	 Flour-647	 conjugated	 anti-mouse	secondary	antibody	for	30	min	on	ice.	Samples	were	washed	twice	and	analysed	by	flow	cytometry.			
ii)	Degradation	Assay	Cells	 were	 labelled	 as	 previously	 described	 with	 an	 APC-conjugated	 PD-L1	specific	 (29E.2A3)	 or	MHC	 class	 I-specific	 antibody	 (W6/32).	After	washing	 as	described	cells	were	replated	in	complete	medium	and	incubated	at	370C,	in	the	presence	 or	 absence	 of	 lysosome	 inhibitors	 as	 indicated	 in	 the	 figure	 legends.	The	APC-conjugated	antibody	continues	to	fluoresce	after	internalisation	and	the	degradation	 of	 cell	 surface-labelled	PD-L1	 /	MHC	 class	 I	 is	 reflected	 by	 loss	 of	fluorescence	intensity	over	time.		At	the	indicated	times,	cells	were	harvested	by	brief	 incubation	with	Tryple-Express,	washed	twice	and	fixed	for	10	min	in	4%	PFA	prior	to	analysis	by	flow	cytometry.		
iii)	Recycling	Assay	1	Cell	 surface	 PDL1	 was	 labelled	 with	 unconjugated	 anti-PDL1	 (29E.2A3,	Biolegend)	for	1	h	on	ice	as	described.	Cells	were	incubated	at	370C	for	30	min	to	allow	endocytosis	of	antibody-labelled	PD-L1.	After	washing,	remaining	surface	bound	antibody	was	 stripped	by	 two	 rounds	of	 resuspension	 in	 low	pH	buffer	(0.5	 M	 NaCl,	 0.5%	 acetic	 acid,	 pH	 2.5-2.8)	 for	 2	 min	 on	 ice,	 followed	 by	neutralisation	with	RPMI/5%	FCS/30mM	Hepes.		A	baseline	sample	was	kept	on	ice	and	cells	were	returned	 to	370C	 to	allow	PD-L1	recycling.	Samples	 taken	at	the	 indicated	 times	were	 stained	with	 Alexa	 Flour-647	 conjugated	 anti-mouse	secondary	antibody	for	30	min	on	ice	and	analysed	by	flow	cytometry.			
iv)	Recycling	Assay	2	Cell	 surface	 PDL1	was	 stained	with	 an	 AF488-conjugated	 anti-PD-L1	 antibody	(Abcam)	on	ice	for	1	h	then	washed	twice.	A	pre-endocytosis	control	sample	was	kept	 on	 ice	 and	 remaining	 cells	 were	 incubated	 at	 370C	 for	 30	 min	 to	 allow	endocytosis	 of	 antibody-labelled	 PD-L1.	 The	 remaining	 surface-bound	 AF488-conjugated	anti-PD-L1	antibody	was	quenched	by	incubation	with	an	anti-AF488	antibody	(Invitrogen)	for	1	h	on	ice.	Cells	were	washed	twice	and	returned	370C	to	allow	PD-L1	recycling.	Samples	taken	at	the	indicated	times	were	returned	to	ice,	split	and	incubated	with	or	without	anti-AF488	antibody	to	quench	anti-PD-L1-AF488	recycled	to	the	cell	surface.		Samples	were	analysed	by	flow	cytometry.		After	 normalisation	 for	 incomplete	 quenching	 by	 subtracting	 the	 quenchable	AF488	 signal	 present	 at	 baseline,	 the	 proportion	 of	 recycled	 PD-L1	 was	calculated	from	the	‘quenchable’	AF488	fluorescence	intensity	at	each	time	point	(MFI	 of	 non-requenched	 sample	 –	 MFI	 of	 requenched	 sample)	 divided	 by	 the	fluorescence	intensity	of	PD-L1	internalised	during	the	endocytosis	step.	
	
Immunofluorescence	MDA-MB-231	cells	were	cultured	on	coverslips	overnight,	with	or	without	IFN-γ	and	with	or	without	50nM	Concanamycin	A.	For	mixed	cultures,	one	cell	line	was	labeled	 with	 CFSE	 as	 per	 manufacturer’s	 instructions	 and	 cultured	 with	unlabeled	 cells	 at	 a	 1:1	 ratio.	 Cells	 were	 fixed	 with	 4%	 PFA	 for	 10	 min,	permeablised	with	 0.25%	 tween-20	 in	 PBS	 for	 10	min,	 then	 blocked	with	 5%	BSA,	0.3M	glycine	in	PBST	for	1	hour.	The	cells	were	incubated	with	the	primary	antibody	at	4°C	overnight.	After	washing	3×	with	PBST,	the	cells	were	incubated	with	 the	 fluorescent	 conjugated	 secondary	 antibody	 for	 1	 h	 at	 RT.	 The	 slides	were	 mounted	 with	 Prolong	 Gold	 and	 imaged	 on	 a	 Nikon	 C2	 confocal	microscope.		
Generation	and	culture	of	NY-ESO-1	specific	CD8+	T-lymphocyte	clones	CD8+	 T-lymphocyte	 clones	 specific	 for	 the	 NY-ESO-1	 HLA-Cw3-restricted	peptide	NY-ESO-192–100	and	the	HLA-A2-restricted	peptide	NY-ESO-1157-165	were	
generated	 from	 patients	 who	 consented	 to	 participate	 in	 a	 clinical	 research	protocol	 approved	by	Austin	Health	Human	Research	Ethics	Committee	 (HREC	H2006/02633).	 All	 ethical	 regulations	 were	 complied	 with.	 PBMC	 were	stimulated	with	1	×	10−6	M	peptide	(Mimotopes),	and	cultured	for	10	days	in	the	presence	 of	 25	 IU/ml	 IL-2	 (Peprotech).	 Specific	 cells	 were	 labelled	 with	 a	fluorescent	 tetramer	 (comprising	 the	 relevant	 peptide	 and	 HLA,	 (TCMetrix,	Epalinges,	Switzerland)	and	single-cell	sorted	using	a	MoFlow	cytometer.	Clones	were	expanded	with	pooled,	 autologous	healthy	donor	PBMC	as	 feeder	 cells,	 1	μg/ml	phytohaemagglutinin-L	(PHA-L	(Sigma))	and	600	IU/ml	IL-2	(Cetus).	After	approximately	20	days,	1–10	×	103	clones	were	restimulated	in	the	presence	of	autologous	 PBMC	 as	 feeder	 cells,	 PHA-L	 and	 IL-2,	 as	 described	 above.	 Clone	specificity	was	confirmed	by	tetramer	staining.	T-lymphocyte	clones/lines	were	cultured	 in	 RPMI-1640	media	 supplemented	with	 2	mM	 Glutamax,	 100	 IU/ml	Penicillin,	 100	 μg/ml	 Streptomycin,	 20	 mM	 HEPES,	 1	 %	 nonessential	 amino	acids,	 1	 mM	 sodium	 pyruvate,	 55	 μM	 β-mercaptoethanol,	 and	 10	 %	 human	serum	(TCRPMI).		IL-2	(100	IU/ml)	was	added	and	replaced	every	3	days.	
Intracellular	cytokine	staining	of	antigen-activated	T-lymphocytes	NY-ESO-1	antigen-specific	T-lymphocyte	clones	were	incubated	with	melanoma	cells	 for	 16	 to	 24	 h	 prior	 to	 addition	 of	 10	 μg/ml	 brefeldin	 A	 to	 the	 culture	medium	 for	 a	 further	 6	 h.	 To	 stain	 surface	 markers,	 cells	 were	 washed	 and	labelled	with	live/dead	fixable	violet	stain	(Invitrogen)	and	antibodies	targeting	CD3	(BV510),	CD8	(FITC)	and	PD-1(APC)	 in	PBS	 for	15	min	 in	 the	dark	at	4°C,	washed	 and	 then	 fixed	 and	 permeabilised	 with	 BD	 Cytofix/Cytoperm	 reagent	(BD	Biosciences)	for	20	min	at	4°C.		Cells	were	stained	with	anti-TNFα	(PE-Cy7)	and	 Perforin	 in	 permeabilisation	 solution	 (BD	 Biosciences)	 for	 25	 min	 and	washed	 prior	 to	 flow	 cytometry	 analysis.	 Data	were	 acquired	 on	 a	 FACSVerse	Flow	Cytometer	using	FACSDiva	software	and	analysed	using	FlowJo.	
Cytokine	Secretion	20,000	INF-γ	pretreated	melanoma	cells	per	well	were	plated	 in	96-well	plates	and	10,000	NY-ESO-1	 antigen-specific	 CTLs	were	 added.	 	 Both	melanoma	 cells	and	 T-lymphocytes	 were	 washed	 prior	 to	 plating	 to	 remove	 potential	
contaminating	traces	of	INF-γ	or	IL-2	from	the	media.	Cells	were	co-cultured	for	72	 hours	 and	 10ug/ml	 of	 anti-PD-1	 antibody	 was	 included	 in	 the	 co-culture	where	indicated.	100ul	of	200ul	total	supernatant	was	removed,	transferred	to	a	fresh	 96well	 plate,	 frozen	 and	 sent	 to	 elisakit.com	 for	 analysis.	 Cytokines	 and	chemokines	were	quantified	by	multiplex	bead	array	using	a	 ‘Cytokine	25-plex	Human	Panel’	 on	 a	 Luminex	 platform.	Assays	were	 performed	 in	 duplicate	 for	untreated	control	cells	and	in	triplicate	for	all	other	samples.	To	evaluate	for	PD-L1	 dependent	 effects	 of	 CMTM6,	 cytokines/chemokines	 detected	were	 filtered	for	 those	 present	 at	 higher	 levels	 following	 inclusion	 of	 anti-PD-1	 in	 the	 co-culture	 (shown	 in	 Figure	 4g	 and	 Extended	 data	 Fig.	 10f).	 	 The	 cytokine	concentration	 in	 co-cultures	 with	 CMTM6-depleted	 cells	 was	 compared	 to	control	cell	cultures	and	p-values	calculated	in	Prism	using	unpaired	two-tailed	t-tests	with	Holm-Sidak	correction	for	multiple	testing.		
Analysis	of	tumour	killing	by	NY-ESO-1	antigen-specific	T-lymphocytes	Five	or	 ten	 thousand	melanoma	cells	per	well	were	plated	 in	a	 flat	bottom	96-well	 plate.	 T-lymphocytes	were	 added	 to	 selected	wells	 to	 give	 the	 effector	 to	target	(E:T)	ratios	indicated	in	the	figure	legends.	Samples	were	incubated	at	37	°C	for	either	24h	(Extended	Data	Fig	10c)	or	48h	(Extended	Data	Fig	10d/e).	T-lymphocytes	were	resuspended	by	gentle	pipetting	and	then	removed.	The	plate	was	washed	once	with	PBS.	MTS	reagent	(CellTiter	96®	AQueous	One	Solution	Cell,	Promega)	was	added	and	samples	incubated	for	1–2	h	at	37°C.	Absorbance	at	 490	 nm	was	measured	 and	 normalized	 to	 melanoma	 samples	 incubated	 in	absence	of	T-lymphocytes	for	each	cell	line	to	give	the	percentage	of	viable	cells.	
Jurkat	co-culture	IL-2	assays	WM-852	PD-L1	and	CMTM6	knockout	clones	and	parental	Cas9	expressing	WM-852	cells	transduced	with	a	control	vector	(pKLV	PGKpuro2ABFP)	were	treated	with	IFN-γ	for	24	hours.	1×104	WM-852	cells	were	plated	into	96	well	plates	in	100µL	of	media	and	allowed	to	adhere	for	24	hours.	Jurkats	were	activated	with	25ng/mL	of	PMA	and	1µg/mL	of	PHA	for	24	hours,	then	added	to	WM-852	cells	at	a	ratio	of	2:1	or	4:1	Jurkat:WM-852.	The	cell	culture	media	was	collected	after	
48	 and	 72	 hours	 of	 co-culture.	 The	 levels	 of	 IL-2	were	measured	with	 the	 BD	cytometric	 bead	 array	 assay	 IL-2	 flex	 set	 and	 analysed	 on	 a	 FACSverse	 flow	cytometer.	
Animal	experiments	The	 C57BL/6	 mouse	 melanoma	 cell	 line	 B16F10	 stably	 expressing	 chicken	ovalbumin	 (B16-OVA)	 was	 provided	 by	 Jason	 Waithman	 (Telethon	 Kid’s	Institute).	For	 in	vivo	 experiments,	100,000	cells	were	resuspended	 in	PBS	and	injected	subcutaneously	in	a	100μl	volume	into	female	C57BL/6	mice,	purchased	from	 the	Walter	 and	 Eliza	 Hall	 Institute	 (Melbourne,	 Australia).	 	 The	 survival	endpoint	was	when	tumours	reached	a	size	of	100mm2	.	Mice	were	used	between	6	and	12	weeks	of	age	and	the	number	of	mice	per	group	was	selected	to	provide	sufficient	 statistical	 power	 to	 the	 experiment	 according	 to	 the	 expected	biological	 variation.	 In	 the	 experiment	 shown	 in	 Extended	 Data	 Fig.	 10,	 mice	were	matched	according	to	initial	tumour	size	and	randomised	to	treatment	with	anti-CTLA-4	9H10	(150ug/mouse)	or	 isotype	control	antibody	at	days	4,	8	and	12	following	tumour	cell	inoculation.	Investigators	were	not	blinded	as	to	group	allocation.	All	animal	studies	were	approved	in	advance	by	the	Peter	MacCallum	Animal	Ethics	and	Experimentation	Committee	and	all	 ethical	obligations	were	complied	with.	
sgRNA	Target	Sequences	
Gene	 Target	Sequence		PD-L1	(g1)	 GTTCCCAAGGACCTATATG	PD-L1	(g2)	 GAACATGAACTGACATGTC	CMTM6	(g1)	 CAATACACAATCAGTATA	CMTM6	(g2)	 GCCCGGGTCCTCCTCCGTAG	CMTM6	(g3)	 GGTGTACAGCCCCACTACGG	JAK2	(g1)	 GAGCGAACAGTTTCCATC	JAK2	(g2)	 AACCTGGAAGTGGTCCTTC		
	qRT-PCR	primers	
Forward	Primer	(5’→3’)	 Reverse	Primer	(5’→3’)	CMTM6	 ATGAAGGCCAGCAGAGACAG	 GTGTACAGCCCCACTACGGA	PD-L1	 	 GGTGCCGACTACAAGCGAAT	 AGCCCTCAGCCTGACATGTC	GAPDH	 ACAACTTTGGTATCGTGGAAGG	 GCCATCACGCCACAGTTTC		
Data	Availability	The	CRISPR	screen	sequencing	data	has	been	deposited	to	the	NCBI	short	read	archive	under	the	accession	number	PRJNA361422	.		Source	data	re	provided	for	figures	1-4	and	extended	data	figures	2,	5-7,	9&10.	Complete	mass	spectrometry	datasets	are	provided	in	the	supplementary	information.		
Extended	Data	 Figure	 1.	 	 A	 CRISPR/Cas9	 screen	 in	 the	 pancreatic	 cancer	
cell	 line	 BxPC-3	 identifies	 CMTM6	 as	 a	 principal	 regulator	 of	 PD-L1	
expression	
a.	 PD-L1	 is	 expressed	 at	 the	 cell	 surface	 in	 BxPC-3	 cells	 and	 upregulated	following	 treatment	 with	 IFN-γ.	 Cell	 surface	 PD-L1	 was	 analysed	 by	 flow	cytometry	 following	 incubation	 with	 or	 without	 IFN-γ	 500IU/ml	 for	 48	 h.	 b.	BxPC-3	cells	stably	expressing	Cas9	were	mutagenised	by	infection	with	a	pooled	lentiviral	 gRNA	 library	 and	 rare	 PD-L1	 low	 cells	 enriched	 by	 two	 successive	rounds	 of	 FACS	 sorting	 for	mCherry	positive	 (containing	 sgRNA	vector)	 PD-L1	low	 cells.	 	 FACS	 plots	 depict	 sorted	 and	 unsorted	 mutagenised	 populations	stained	 for	PD-L1	 (top	panel)	 and	MHC	class	 I	 control	 (bottom	panel).	c.	 Total	cellular	 PD-L1	 levels	 are	 dramatically	 reduced	 following	 shRNA-mediated	depletion	 of	 CMTM6	 in	 both	 IFN-γ	 treated	 and	 non-IFN-γ	 treated	 cells.		Immunoblot	 for	 PD-L1,	 CMTM6	 and	 HSP60	 control	 in	 MDA-MB-231	 cells	transduced	 with	 shRNAs	 targeting	 CMTM6	 or	 control	 shRNA.	 d.	 Reduced	 cell	surface	PD-L1	following	shRNA-mediated	depletion	of	CMTM6	in	BxPC-3	cells.	
	
Extended	 Data	 Figure	 2.	 Down-regulation	 of	 cell	 surface	 PD-L1	 following	
effective	 RNA	 interference	 (RNAi)-mediated	 depletion	 of	 CMTM6.	 a.		Efficiency	 of	 CMTM6	 depletion	 was	 assessed	 by	 quantitative	 reverse	
transcription	PCR	(qRT-PCR)	in	cells	transduced	with	shRNAs	targeting	CMTM6	or	a	non-targeting	control	shRNA.	The	mean	and	s.e.m.	of	3	technical	replicates	are	 shown.	b.	 RNAi-mediated	 depletion	 of	 CMTM6	 reduces	 cell	 surface	 PD-L1	expression	both	 in	the	presence	and	absence	of	 IFN-γ	stimulation.	 	Cell	surface	PD-L1	was	analysed	by	flow	cytometry	in	the	indicated	cell	lines	transduced	with	lentiviral	 vectors	 encoding	 shRNAs	 targeting	 CMTM6	 or	 control	 shRNA	 (left	panel).	The	adjacent	bar	chart	(right	panel)	shows	fold	change	in	cell	surface	PD-L1	fluorescence	intensity	following	CMTM6	depletion	(mean	and	s.e.m.).	BxPC-3,	HCC-827	and	A375	cells	were	pre-treated	with	IFN-γ	500IU/ml	for	48	h	prior	to	analysis.		Experiments	were	performed	at	least	twice	in	each	cell	type.		
Extended	 Data	 Figure	 3.	 CRISPR/Cas9-mediated	 knockout	 of	 CMTM6	
reduces	cell	surface	PD-L1	expression	in	a	broad	range	of	cancer	cells.	Flow	cytometry	 analysis	 of	 cell	 surface	 PD-L1	 in	 cells	 transduced	 with	 different	sgRNAs	targeting	CMTM6	compared	to	parental	Cas9	expressing	cells.		Cell	lines	depicted	 are	 melanoma	 (A375	 and	 WM-852),	 triple-negative	 breast	 cancer	(MDA-MB-231),	 non-small	 cell	 lung	 cancer	 	 (HCC-827)	 and	 pancreatic	 cancer	(BxPC-3).	 All	 cells	 were	 pre-treated	 with	 IFN-γ	 500IU/ml	 for	 48	 h	 prior	 to	analysis.	Selected	representative	histograms	are	presented	in	Figure	1e.			
Extended	Data	Figure	4.	CMTM6	selectively	regulates	both	constitutive	and	
interferon-induced	PD-L1	without	 compromising	 tumour	 cell	MHC	 class	 I	
expression.	 	 a.	 Cell	 surface	 MHC	 class	 I	 expression	 is	 unaffected	 by	 shRNA-mediated	depletion	of	CMTM6.	Flow	cytometry	analysis	of	 surface	MHC	class	 I	and	 PD-L1	 in	MDA-MB-231	 and	 A375	 cells	 transduced	with	 shRNAs	 targeting	CMTM6	or	control	shRNA.	Cells	were	pre-treated	with	IFN-γ	500IU/ml	for	48	h	prior	to	analysis.	b.	CMTM6	knockout	leads	to	loss	of	both	constitutive	and	IFN-γ-induced	PD-L1	 expression.	 	 Flow	 cytometry	 analysis	 of	 cell	 surface	 PD-L1	 in	Cas9-expressing	MDA-MB-231	cells	transduced	with	sgRNA	targeting	either	PD-L1,	JAK2	or	CMTM6	(red)	compared	to	parental	Cas9-expressing	cells	(blue).	PD-L1	expression	is	reduced	in	both	the	presence	and	absence	of	IFN-γ	stimulation	following	 knockout	 of	 CMTM6.	 In	 contrast,	 knockout	 of	 the	 IFN-γ	 pathway	
component	 JAK2	leads	to	selective	 loss	of	 IFN-γ	 induced	upregulation	of	PD-L1	with	no	effect	on	constitutive	PD-L1	expression.		
Extended	Data	Figure	5.	CMTM6	is	not	regulated	by	IFN-γ	and	co-localises	
with	 PD-L1	 at	 the	 cell	 surface	 in	 both	 the	 presence	 and	 absence	 of	 IFN-γ	
stimulation.		
a.	 CMTM6	 regulates	 cell	 surface	 and	 total	 PD-L1	 levels	 in	 a	 dose-dependent	manner.	Single	cell	clones	isolated	from	WM-852	cells	transduced	with	Cas9	and	an	sgRNA	targeting	CMTM6	were	analysed	by	flow	cytometry	for	surface	PD-L1	and	 immunoblot	 for	 total	 PD-L1	 and	 CMTM6	 following	 incubation	 with	500IU/ml	 IFN-γ	 for	 48	 h	 b.	 qRT-PCR	 analysis	 of	 relative	 CMTM6	 mRNA	expression	in	the	indicated	cell	lines	incubated	with	or	without	IFN-γ	500IU/ml	for	 48	 h	 prior	 to	 analysis.	 Graphs	 show	 mean	 and	 s.e.m.	 of	 two	 biological	replicates	(MDA-MB-231	and	HCC-827)	or	three	technical	replicates	(BxPC-3).	c.	To	confirm	specific	staining	of	endogenous	CMTM6	by	the	anti-CMTM6	antibody,	CMTM6	 knockout	MDA-MB-231	 cells	 were	 labelled	with	 CFSE	 prior	 to	mixing	with	 wildtype	MDA-MB-231	 cells,	 fixed	 and	 immunostained	 for	 CMTM6.	 Scale	bar:	 10µm.	 d.	 MDA-MB-231	 cells	 treated	 with	 IFN-γ	 500IU/ml	 for	 48	 h	 were	fixed,	 immunostained	 for	 CMTM6	 and	 PD-L1	 and	 analysed	 by	 confocal	microscopy.	Scale	bar:	10µm.		
Extended	Data	Figure	6.	CMTM6	shows	functional	specificity	for	PD-L1	
a&b.	CMTM6	specifically	 regulates	PD-L1,	with	no	 effect	 on	 cell	 surface	PD-L2	levels	 in	THP-1	cells.	THP-1	cells	expressing	Cas9	and	transduced	with	CMTM6	sgRNA	were	treated	with	IFN-γ	and	TNF-α	as	 indicated	prior	to	staining	of	cell	surface	PD-L1	and	PD-L2	and	analysis	by	flow	cytometry.		C.	Mass	spectrometry	analysis	 identifies	 PD-L1	 as	 a	 principal	 interaction	partner	 of	 CMTM6.	 CMTM6	was	 immunoprecipitated	 from	 digitonin	 lysates	 of	 IFN-γ-treated	MDA-MB-231	cells,	and	CMTM6	knockout	cells	as	a	control.	Immunoprecipitates	were	analysed	by	 mass	 spectrometry.	 	 Table	 represents	 all	 CMTM6	 interaction	 partners	identified	 by	 at	 least	 3	 unique	 peptides	 and	 absent	 from	 the	 control	immunoprecipitation	 from	CMTM6	knockout	cells.	 	d.	 Increased	degradation	of	EndoH-resistant	PD-L1	species	in	the	absence	of	CMTM6.	IFN-γ	treated	CMTM6	
knockout	 or	 parental	 Cas9-expressing	 WM-852	 cells	 were	 pulse-labelled	 with	35S-methionine/cysteine	for	30	min	before	chase	incubation	at	370C.		PD-L1	was	immunoprecipitated	 from	detergent	 lysates	 at	 the	 indicated	 times.	 	e&f.	 IFN-γ	500IU/ml	 was	 added	 to	 CMTM6	 knockout	 and	 parental	 Cas9-expressing	WM-852	 cells	 and	 samples	 taken	 at	 the	 indicated	 time-points	 for	 analysis	 by	 flow	cytometry.	 A	 representative	 example	 of	 an	 experiment	 done	 in	 biological	triplicate	 is	 shown.	 g.	 Lysates	 of	 CMTM6	 knockout	 cells	 were	 treated	 with	 or	without	 EndoH	 prior	 to	 SDS-PAGE	 analysis	 and	 immunoblot	 to	 assess	modification	of	N-linked	glycans	on	PD-L1	as	 a	marker	of	passage	 through	 the	Golgi.		
Extended	Data	Figure	7:		Cellular	Localisation	of	PD-L1	
a)	Loss	of	CMTM6	leads	to	selective	destabilisation	of	PD-L1	with	no	effect	on	the	stability	 of	 cell	 surface	MHC	 class	 I.	 IFN-γ	 treated	 CMTM6	 knockout	 and	 Cas9	control	 WM-852	 cells	 were	 labelled	 as	 described	 in	 Figure	 3B	 with	 APC-conjugated	 antibodies	 specific	 for	 either	 PD-L1	 or	MHC	 class	 I	 on	 ice	 prior	 to	incubation	at	370C.	 	 	Samples	 taken	at	 the	 indicated	 time-points	were	analysed	by	 flow	 cytometry.	 Experiment	 performed	 twice.	 b)	 MDA-MB-231	 cells	 were	fixed,	immunostained	for	PD-L1	together	with	a	marker	of	the	ER	(CANX),	Golgi	(GM130	 and	 TGN46),	 early	 endosome	 (EEA1)	 or	 late	 endosome/lysosome	(LAMP1)	prior	to	analysis	by	confocal	microscopy.	Scale	bar:	10µm.		
Extended	Data	Figure	8:		PD-L1	endocytosis	and	recycling	assays	
a.	 Internalisation	 assay	 (relates	 to	 data	 presented	 in	 Figure	 3g).	 Cells	 were	labelled	with	 unconjugated	 PD-L1-specific	 antibodies	 at	 40C.	 After	washing	 off	unbound	antibody,	cells	were	 incubated	at	37oC	to	allow	PD-L1	 internalisation.	Remaining	 cell	 surface	 antibody-labelled	 PD-L1	 was	 detected	 with	 an	 AF647-conjugated	anti-mouse	secondary	antibody	and	analysed	by	flow	cytometry.	
b.	Recycling	assay	1.	 	Cell	surface	PD-L1	in	IFN-γ	treated	CMTM6	knockout	and	Cas9	 control	 WM-852	 cells	 was	 labelled	 with	 an	 unconjugated	 PD-L1	 specific	antibody	 and	 allowed	 to	 internalise	 for	 30	 min	 at	 370C	 as	 described	 in	 a.		Remaining	cell-surface	bound	antibody	was	stripped	by	washing	in	pH	2.5	buffer	and	cells	were	either	kept	on	ice	(post-strip	baseline)	or	re-incubated	at	370C	for	
the	 indicated	 times.	 	 Recycled	 PD-L1	 was	 detected	 with	 an	 AF647-conjugated	anti-mouse	secondary	antibody.	
c.	Recycling	assay	2	(relates	to	data	presented	in	Figure	3h).	Cells	were	labelled	with	 an	 AF488-conjugated	 PD-L1	 specific	 antibody,	 washed	 and	 incubated	 at	370C	 to	 allow	 endocytosis.	 Remaining	 cell	 surface	 AF488	 was	 quenched	 by	incubation	with	an	AF488-specific	antibody	for	1	h	on	ice	prior	to	reincubation	at	 370C	 to	 allow	 recycling	 of	 antibody-labelled	 PD-L1.	 Samples	were	 split	 and	incubated	with	or	without	an	AF488-specific	antibody	for	1	h	on	ice	to	re-quench	cell	 surface	 AF488.	 Recycled	 PD-L1	 was	 detected	 by	 the	 reappearance	 of	 cell	surface	 ‘quenchable’	 AF488	 signal.	 	 After	 normalisation	 for	 incomplete	quenching	 at	 baseline	 by	 subtracting	 the	 ‘quenchable’	 AF488	 fluorescence	 at	time	 zero,	 the	 fluorescence	 intensity	 of	 recycled	PD-L1	 at	 each	 time-point	was	compared	 to	 that	 of	 the	 total	 internalised	 PD-L1	 after	 the	 endocytosis	 step	 to	calculate	the	proportion	of	PD-L1	recycled.			
Extended	Data	Figure	9.	PD-L1	is	targeted	for	degradation	in	the	lysosome	
following	depletion	of	CMTM6		
a/b.	 PD-L1	 is	 targeted	 for	 lysosome-dependent	 degradation	 in	 the	 absence	 of	CMTM6.	 IFN-γ	 treated	 CMTM6	 knockout	 and	 Cas9	 control	WM-852	 cells	were	labelled	with	APC-conjugated	PD-L1-specific	antibody	as	in	Figure	3b.	Cells	were	chased	 at	 370C	 in	 the	 presence	 or	 absence	 of	 either	 50nM	 Concanamycin-A,	50µM	Chloroquine	or	400nM	Bafilomycin	A1.	c.	IFN-γ	treated	CMTM6	knockout	and	 Cas9	 control	 WM-852	 cells	 were	 incubated	 with	 Con-A,	 Chloroquine	 or	Bafilomycin-A1	for	16	h	prior	to	analysis	by	immunoblot.	d.	Following	inhibition	of	 lysosomal	 degradation	 PD-L1	 remains	 sequestered	 intracellularly	 in	 the	absence	of	CMTM6.	MDA-MB-231	cells	expressing	shRNAs	targeting	CMTM6	or	control	shRNA	were	incubated	with	50nM	Concanamycin-A	(ConA)	for	16	h	prior	to	flow	cytometry	analysis	for	cell	surface	PD-L1.	e.	Jurkat	cells	co-cultured	with	a	CMTM6	knockout	tumour	show	enhanced	Il-2	secretion.		Jurkat	cells	were	pre-activated	 overnight	with	 PMA	 and	 PHA	 and	 co-cultured	with	 PD-L1	 knockout,	CMTM6	 knockout	 or	 control	 vector	 expressing	WM-852	 Cas9	 cells	 pre-treated	with	500IU/ml	 IFN-γ	 for	24h	 to	upregulate	PD-L1	expression.	 Il-2	 levels	 in	 the	
culture	supernatant	were	measured	by	cytometric	bead	array	after	48	h	and	72	h	co-culture	 of	 Jurkat	 cells	 and	 tumour.	 Graphs	 show	 percent	 change	 in	 Il-2	secretion	compared	 to	control	cell	 co-culture	 (mean	and	s.e.m.	of	experimental	duplicates)	 f-h.	 Reduction	 in	 cell	 surface	 PD-L1	 following	 knockout	 or	knockdown	of	CMTM6	in	NY-ESO-1	expressing	melanoma	cell	lines	used	in	T-cell	co-culture	 assays.	 All	 cells	 were	 treated	 with	 IFN-γ	 prior	 to	 flow	 cytometry	analysis	 for	 cell	 surface	 PD-L1.	 f.	 A375	 cells	 stably	 expressing	 Cas9	 were	transduced	with	 two	 different	 sgRNA	 targeting	 CMTM6	 and	 CMTM6	 knockout	clones	 isolated	 by	 dilution	 cloning.	 	g.	 Patient-derived	melanoma	 cell	 line	 LM-MEL-44	was	 transduced	with	CMTM6	 targeting	or	 control	 shRNA.	 	 	h.	 Patient-derived	melanoma	cell	 line	LM-MEL-53	was	sequentially	 transduced	with	Cas9	and	 either	 one	 of	 two	 different	 sgRNAs	 targeting	 CMTM6,	 an	 sgRNA	 targeting	PD-L1	or	a	control	vector.				
Extended	Data	Figure	10:	CMTM6	regulates	tumour-specific	T	cell	activity	
by	regulating	PD-L1	levels	
a.	Schematic	overview	of	T-cell	and	tumour	co-culture	assays	to	evaluate	PD-L1-dependent	inhibition	of	T-cell	activity.	b.	Increased	PD-1	expression	on	NY-ESO-192-100	 HLA-CW3	 restricted	 T-lymphocytes	 following	 24	 h	 co-culture	 with	 LM-MEL-53	 melanoma.	 	 Staining	 with	 APC-conjugated	 anti-PD-1	 antibody	 is	completely	blocked	following	addition	of	anti-PD-1	antibody	nivolumab	(BMS)	at	a	 saturating	 concentration	 (10µg/ml).	 c-f.	 CMTM6	 regulates	 the	 anti-tumour	activity	 of	 NY-ESO-1	 antigen-specific	 T	 lymphocytes	 c-g.	 NY-ESO-192-100	 HLA-CW3	restricted	or	NY-ESO-1157-165	HLA-A2	restricted	CTLs	were	incubated	with	the	indicated	melanoma	cells	at	an	effector:target	ratio	of	1:1	(c&e)	or	1:2	(d)	for	24-48	h	at	37	°C,	then	washed	off.	CTL	mediated	tumour	lysis	was	determined	by	MTS	assay	and	normalized	to	control	wells	with	no	CTLs..	Error	bars	represent	SEM	(n	=	3).	*	p	<	0.05.	f&g.	Enhanced	T-cell	activation	following	co-culture	with	a	 CMTM6-depleted	 cancer	 cells.	 f.	 NY-ESO-192-100	 HLA-CW3	 restricted	 T-lymphocytes	were	cultured	with	CMTM6	sgRNA,	PD-L1	sgRNA	or	control	vector	transduced	LM-MEL-53	melanoma	cells	stably	expressing	Cas9	for	24h	prior	to	incubation	with	Brefeldin	A	for	6	h	and	 intracellular	staining	for	TNF-α.	Where	indicated,	 10µg/ml	 nivolumab	 (anti-PD-1	 antibody)	 was	 added	 to	 the	 co-
cultures.	 g.	 Supernatants	 from	 3	 day	 co-cultures	 of	 NY-ESO-192-100	 CTLs	 and	control	vector	or	CMTM6	sgRNA	transduced	LM-MEL-53	cells	were	analysed	by	multiplex	 bead	 immunoassay	 (Luminex).	 Chemokines	 detected	 at	 increased	levels	following	inclusion	of	10µg/ml	nivolumab	(anti-PD-1	antibody)	in	the	co-cultures	are	shown.	Graphs	show	triplicates	(mean	+	s.e.m).	*	p	<	0.05,	unpaired	two-tailed	t-test	with	Holm-Sidak	correction	for	multiple	testing.	h.	Efficiency	of	CMTM6	depletion	was	assessed	by	qRT-PCR	 in	B16-OVA	cells	 transduced	with	shRNA	 targeting	 CMTM6	 or	 a	 non-targeting	 control	 shRNA.	 i&j.	 Growth	 of	CMTM6-deficient	 and	 control	 shRNA	 expressing	 B16-OVA	 tumours	 injected	subcutaneously	 in	C57BL/6	mice.	Data	are	 from	two	 independent	experiments.	Where	 indicated,	 mice	 were	 treated	 with	 anti-CTLA-4	 or	 isotype	 control	antibody	from	day	4	after	tumour	cell	injection.			
